Advertisement
News
Advertisement

Valeant Pharmaceuticals Completes Acquisition of iNova

Thu, 12/22/2011 - 4:36am
Bio-Medicine.Org

MISSISSAUGA, Ontario, Dec. 22, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that effective December 21, 2011, the company completed its previously announced acquisition of iNova, from Archer Capital, Ironbridge and other minority management shareholders.

BofA Merrill Lynch and Baker & McKenzie acted as Valeant's advisors in connection with this transaction.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:

Laurie W. Little

949-461-6002

laurie.little@valeant.com     

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading